Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| EA9171 | Alliance | BLAST MRD CML 1 Trial: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML and Persistently Detectable MRD | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA9181 | ECOG-ACRIN | A Phase III Randomized Trial of Steroids +Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia in Adults | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA9213 | ECOG-ACRIN | A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EAA171 | ECOG-ACRIN | Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EAA172 | ECOG-ACRIN | Phase 1/2 Study of Daratumumab, Bortezomib, Dexamethasone with or without Venetoclax in Relapsed/Refractory Multiple Myeloma with Assessment for t(11;14) Status | Adult CIRB - Late Phase Emphasis | Completed | |
| EAA173 | ECOG-ACRIN | Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EAA181 | ECOG-ACRIN | Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended For Early Autologous Transplantation | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EAE161 | ECOG-ACRIN | Perfusion CT to Predict Progression-free Survival and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma | Adult CIRB - Late Phase Emphasis | Completed | |
| EAF151 | ECOG-ACRIN | Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EAF223 | ECOG-ACRIN | Phase II Glioblastoma Accelerated Biomarkers Learning Environment Trial (GABLE) | Adult CIRB - Late Phase Emphasis | Available to Open |